tratamento clínico da neurorretinite subaguda difusa unilateral com albendazol clinical treatment of diffuse unilateral subacute neuroretinitis with albendazole

Clicks: 354
ID: 176867
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #35 of 137 articles by views in introducing innodb cluster: learning the mysql high availability stack

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 137 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJETIVO: Descrever a evolução de uma série de casos de neurorretinite subaguda difusa unilateral (NSDU) tratados com albendazol. MÉTODOS: Relato de série de casos intervencionista. Os autores desenvolveram protocolo de ensaio clínico não controlado, para estudar a evolução clínica de casos de neurorretinite subaguda difusa unilateral tratados com albendazol. Segundo os critérios do protocolo, foram selecionados seis pacientes até o momento desta publicação, que serão descritos separadamente. RESULTADOS: Dos seis pacientes estudados, quatro apresentavam larva. Todos os seis pacientes tratados com a droga anti-helmíntica apresentaram melhora da acuidade visual e das lesões coriorretinianas multifocais. As larvas identificadas nos pacientes foram inativadas com o tratamento. Nenhum efeito colateral foi observado. CONCLUSÕES: A terapia anti-helmíntica com albendazol parece ser benéfica e segura para pacientes com neurorretinite subaguda difusa unilateral. Mais estudos são necessários para avaliar a eficácia do albendazol no tratamento da neurorretinite subaguda difusa unilateral.
PURPOSE: To describe the evolution of a series of cases of diffuse unilateral subacute neuroretinitis (DUSN) treated with albendazole. METHODS: Interventional case series. The authors developed a non-randomized clinical trial protocol to investigate the clinical evolution of diffuse unilateral subacute neuroretinitis cases treated with albendazole. According to protocol criteria up to now, six patients were selected that will be described separately. RESULTS: Of the six studied patients, four presented the worm. All six patients treated with the antiparasitic drug showed improvement of visual acuity and of chorioretinal scars. During the weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed. CONCLUSIONS: The antiparasitic drug albendazole seems to be beneficial and safe in patients with diffuse unilateral subacute neuroretinitis. More studies are necessary to evaluate the effectiveness of albendazole in the treatment of diffuse unilateral subacute neuroretinitis.
Reference Key
malaguido2007arquivostratamento Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Marcus Rudolph Malaguido, Antonio Marcelo Barbante Casella, Daniela Rossetto Garcia Malaguido
Are you one of these authors? Claim your profile
Journal introducing innodb cluster: learning the mysql high availability stack
Year 2007
DOI
10.1590/S0004-27492007000500016
URL
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492007000500016
Keywords
albendazole retina

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.